Aizhan Tastanova

Aizhan Tastanova

Auto-generated profile, based on publicly available information

Aizhan Tastanova

Department of Dermatology, University Hospital Zurich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Cancer Cell
Verified
Journal Article
Closed access
EREgle Ramelyte
Egle Ramelyte
ATAizhan Tastanova
Aizhan Tastanova
ZBZsolt Balázs
Zsolt Balázs
DIDesislava Ignatova
Desislava Ignatova
PTPatrick Turko
Patrick Turko
Reinhard DummerReinhard Dummer
Reinhard Dummer

18 April 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
ATAizhan Tastanova
Aizhan Tastanova
MFMarc Folcher
Marc Folcher
MMMarius Müller
Marius Müller
GCGieri Camenisch
Gieri Camenisch
APAaron Ponti
Aaron Ponti
MFMartin Fussenegger
Martin Fussenegger
Diagnosis marks the beginning of any successful therapy. Because many medical conditions progress asymptomatically over extended periods of time, their timely diagnosis remains difficult, and this adversely affects patient prognosis. Focusing on hypercalcemia associated with cancer, we aimed to develop a synthetic biology-inspired biomedical tattoo using engineered cells that would (i) monitor long-term blood calcium concentration, (ii) detect onset of mild hypercalcemia, and (iii) respond via subcutaneous accumulation of the black pigment melanin to form a visible tattoo. For this purpose, we designed cells containing an ectopically expressed calcium-sensing receptor rewired to a synthetic signaling cascade that activates expression of transgenic tyrosinase, which produces melanin in response to persistently increased blood Ca2+. We confirmed that the melanin-generated color change produced by this biomedical tattoo could be detected with the naked eye and optically quantified. The system was validated in wild-type mice bearing subcutaneously implanted encapsulated engineered cells. All animals inoculated with hypercalcemic breast and colon adenocarcinoma cells developed tattoos, whereas no tattoos were seen in animals inoculated with normocalcemic tumor cells. All tumor-bearing animals remained asymptomatic throughout the 38-day experimental period. Although hypercalcemia is also associated with other pathologies, our findings demonstrate that it is possible to detect hypercalcemia associated with cancer in murine models using this cell-based diagnostic strategy.

29 August 2024 in Nature Cancer
Verified
Journal Article
Open access
PDF file
FDFlorentia Dimitriou
Florentia Dimitriou
PCPhil Cheng
Phil Cheng
ASAnnalisa Saltari
Annalisa Saltari
KSKatrin Schaper-Gerhardt
Katrin Schaper-Gerhardt
RSRamon Staeger
Ramon Staeger
Reinhard DummerReinhard Dummer
Reinhard Dummer
Immune checkpoint inhibitors are standard-of-care for the treatment of advanced melanoma, but their use is limited by immune-related adverse events. Proteomic analyses and multiplex cytokine and chemokine assays from serum at baseline and at the adverse event onset indicated aberrant T cell activity with differential expression of type I and III immune signatures. This was in line with the finding of an increase in the proportion of CD4+ T cells with IL-17A expression at the adverse event onset in the peripheral blood using flow cytometry. Multiplex immunohistochemistry and spatial transcriptomics on immunotherapy-induced skin rash and colitis showed an increase in the proportion of CD4+ T cells with IL-17A expression. Anti-IL-17A was administered in two patients with mild myocarditis, colitis and skin rash with resolution of the adverse events. This study highlights the potential role of type III CD4+ T cells in adverse event development and provides proof-of-principle evidence for a clinical trial using anti-IL-17A for treating adverse events.

22 March 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
OEOssia M. Eichhoff
Ossia M. Eichhoff
CSCorinne I. Stoffel
Corinne I. Stoffel
JKJan Käsler
Jan Käsler
LBLuzia Briker
Luzia Briker
PTPatrick Turko
Patrick Turko
MLMitchell Levesque
Mitchell Levesque
Clinical management of melanomas with NRAS mutations is challenging. Targeting MAPK signaling is only beneficial to a small subset of patients due to resistance that arises through genetic, transcriptional, and metabolic adaptation. Identification of targetable vulnerabilities in NRAS-mutated melanoma could help improve patient treatment. Here, we used multiomics analyses to reveal that NRAS-mutated melanoma cells adopt a mesenchymal phenotype with a quiescent metabolic program to resist cellular stress induced by MEK inhibition. The metabolic alterations elevated baseline reactive oxygen species (ROS) levels, leading these cells to become highly sensitive to ROS induction. In vivo xenograft experiments and single-cell RNA sequencing demonstrated that intratumor heterogeneity necessitates the combination of a ROS inducer and a MEK inhibitor to inhibit both tumor growth and metastasis. Ex vivo pharmacoscopy of 62 human metastatic melanomas confirmed that MEK inhibitor–resistant tumors significantly benefited from the combination therapy. Finally, oxidative stress response and translational suppression corresponded with ROS-inducer sensitivity in 486 cancer cell lines, independent of cancer type. These findings link transcriptional plasticity to a metabolic phenotype that can be inhibited by ROS inducers in melanoma and other cancers. Significance: Metabolic reprogramming in drug-resistant NRAS-mutated melanoma cells confers sensitivity to ROS induction, which suppresses tumor growth and metastasis in combination with MAPK pathway inhibitors.

1 June 2021 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
ADAndreas Dzung
Andreas Dzung
PCPhil Cheng
Phil Cheng
CSCorinne Stoffel
Corinne Stoffel
ATAizhan Tastanova
Aizhan Tastanova
PTPatrick Turko
Patrick Turko
PBPhilipp P. Bosshard
Philipp P. Bosshard

1 July 2021 in The Journal of Molecular Diagnostics
Verified
Journal Article
Open access
ATAizhan Tastanova
Aizhan Tastanova
CSCorinne Isabelle Stoffel
Corinne Isabelle Stoffel
ADAndreas Dzung
Andreas Dzung
PCPhil Cheng
Phil Cheng
EBElisa Bellini
Elisa Bellini
MLMitchell Levesque
Mitchell Levesque
Real-time RT-PCR remains a gold standard in the detection of various viral diseases. In the coronavirus 2019 pandemic, multiple RT-PCR–based tests were developed to screen for viral infection. As an emergency response to increasing testing demand, we established a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) PCR diagnostics platform for which we compared different commercial and in-house RT-PCR protocols. Four commercial, one customized, and one in-house RT-PCR protocols were evaluated with 92 SARS-CoV-2–positive and 92 SARS-CoV-2–negative samples. Furthermore, economical and practical characteristics of these protocols were compared. In addition, a highly sensitive digital droplet PCR (ddPCR) method was developed, and application of RT-PCR and ddPCR methods on SARS-CoV-2 environmental samples was examined. Very low limits of detection (1 or 2 viral copies/μL), high sensitivities (93.6% to 97.8%), and high specificities (98.7% to 100%) for the tested RT-PCR protocols were found. Furthermore, the feasibility of downscaling two of the commercial protocols, which could optimize testing capacity, was demonstrated. Tested commercial and customized RT-PCR detection kits show very good and comparable sensitivity and specificity, and the kits could be further optimized for use on SARS-CoV-2 viral samples derived from human and surface swabbed samples.